FDA approves Rhapsido (remibrutinib) as the first treatment specifically for adults with symptomatic dermographism not adequately controlled by H1 antihistamines.
FDA Approves Rhapsido for Symptomatic Dermographism
FDA approves Rhapsido (remibrutinib) as the first treatment specifically for adults with symptomatic dermographism not adequately controlled by H1 antihistamines.